tiprankstipranks
Trending News
More News >
Vertex Pharmaceuticals Inc. (VRTX)
:VRTX
US Market
Advertisement

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Compare
6,377 Followers
See the Price Targets and Ratings of:

VRTX Analyst Ratings

Moderate Buy
25Ratings
Moderate Buy
15 Buy
10 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$486.24
▲(26.05% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $486.24 with a high forecast of $624.00 and a low forecast of $401.00. The average price target represents a 26.05% change from the last price of $385.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"400":"$400","625":"$625","456.25":"$456.3","512.5":"$512.5","568.75":"$568.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$624.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":486.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$486.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":401,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$401.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[400,456.25,512.5,568.75,625],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401,418.15384615384613,435.3076923076923,452.46153846153845,469.61538461538464,486.7692307692308,503.9230769230769,521.0769230769231,538.2307692307693,555.3846153846154,572.5384615384615,589.6923076923076,606.8461538461538,{"y":624,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401,407.55692307692306,414.11384615384617,420.6707692307692,427.22769230769234,433.7846153846154,440.34153846153845,446.89846153846156,453.4553846153846,460.0123076923077,466.5692307692308,473.12615384615384,479.68307692307695,{"y":486.24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401,401,401,401,401,401,401,401,401,401,401,401,401,{"y":401,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":495.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.12,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$624.00Average Price Target$486.24Lowest Price Target$401.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on VRTX
Morgan Stanley
Morgan Stanley
$439
Hold
13.81%
Upside
Reiterated
09/29/25
Vertex Pharmaceuticals Hold Rating: Key Factors and Challenges in the IgA Nephropathy Market
Leerink Partners Analyst forecast on VRTX
Leerink Partners
Leerink Partners
$458$456
Buy
18.21%
Upside
Upgraded
09/26/25
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at LeerinkVertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
William Blair Analyst forecast on VRTX
William Blair
William Blair
Buy
Reiterated
09/25/25
Vertex Pharmaceuticals' Strategic Acquisition and FDA Breakthrough Designation Boosts Buy RatingWe note that Filspari (full approval), Fabhalta, Vanrafia are already approved for IgAN, indicating the FDA views data from the Phase II RUBY-3 clinical trial, which was used as the basis for granting BTD, as meaningfully differentiated from available therapies. We believe there is a case to be made that the FDA sees B-cell modulators as a class to fulfill an unmet need in IgAN despite Filspari full approval, given BTD is also held by Vera’s (VERA $27.44) atacicept and Otsuka’s (OTSKY $26.66) sibeprenlimab. For IgAN, once monthly subcutaneous 80 mg pove is currently under investigation in the Phase III RAINIER study, which has a prespecified interim analysis (IA) evaluating the urine- protein-to-creatinine ratio (UPCR) after a specified number of participants reach 36 weeks of treatment.
Bank of America Securities Analyst forecast on VRTX
Bank of America Securities
Bank of America Securities
$565
Buy
46.47%
Upside
Reiterated
09/23/25
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
Evercore ISI Analyst forecast on VRTX
Evercore ISI
Evercore ISI
$510$475
Buy
23.14%
Upside
Reiterated
09/11/25
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
BMO Capital Analyst forecast on VRTX
BMO Capital
BMO Capital
$530
Buy
37.40%
Upside
Reiterated
09/11/25
Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic PositioningRobust pipeline updates and our ongoing Journavx script tracking underpin our Outperform rating and a target price of $530.
Citi
$550
Buy
42.58%
Upside
Reiterated
09/10/25
Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
Raymond James Analyst forecast on VRTX
Raymond James
Raymond James
$401
Hold
3.96%
Upside
Initiated
09/02/25
Vertex Pharmaceuticals initiated with a Market Perform at Raymond JamesVertex Pharmaceuticals initiated with a Market Perform at Raymond James
Bernstein
Hold
Reiterated
08/22/25
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Goldman Sachs Analyst forecast on VRTX
Goldman Sachs
Goldman Sachs
$624
Buy
61.77%
Upside
Reiterated
08/11/25
Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on VRTX
Canaccord Genuity
Canaccord Genuity
$424$411
Hold
6.55%
Upside
Reiterated
08/06/25
Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord
Guggenheim
$558$546
Buy
41.55%
Upside
Reiterated
08/06/25
Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Wells Fargo Analyst forecast on VRTX
Wells Fargo
Wells Fargo
$460
Buy
19.25%
Upside
Upgraded
08/06/25
Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position
Truist Financial Analyst forecast on VRTX
Truist Financial
Truist Financial
$520$490
Buy
27.03%
Upside
Reiterated
08/05/25
Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on VRTX
H.C. Wainwright
H.C. Wainwright
$550$478
Buy
23.92%
Upside
Reiterated
08/05/25
Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on VRTX
Morgan Stanley
Morgan Stanley
$439
Hold
13.81%
Upside
Reiterated
09/29/25
Vertex Pharmaceuticals Hold Rating: Key Factors and Challenges in the IgA Nephropathy Market
Leerink Partners Analyst forecast on VRTX
Leerink Partners
Leerink Partners
$458$456
Buy
18.21%
Upside
Upgraded
09/26/25
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at LeerinkVertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
William Blair Analyst forecast on VRTX
William Blair
William Blair
Buy
Reiterated
09/25/25
Vertex Pharmaceuticals' Strategic Acquisition and FDA Breakthrough Designation Boosts Buy RatingWe note that Filspari (full approval), Fabhalta, Vanrafia are already approved for IgAN, indicating the FDA views data from the Phase II RUBY-3 clinical trial, which was used as the basis for granting BTD, as meaningfully differentiated from available therapies. We believe there is a case to be made that the FDA sees B-cell modulators as a class to fulfill an unmet need in IgAN despite Filspari full approval, given BTD is also held by Vera’s (VERA $27.44) atacicept and Otsuka’s (OTSKY $26.66) sibeprenlimab. For IgAN, once monthly subcutaneous 80 mg pove is currently under investigation in the Phase III RAINIER study, which has a prespecified interim analysis (IA) evaluating the urine- protein-to-creatinine ratio (UPCR) after a specified number of participants reach 36 weeks of treatment.
Bank of America Securities Analyst forecast on VRTX
Bank of America Securities
Bank of America Securities
$565
Buy
46.47%
Upside
Reiterated
09/23/25
Vertex Pharmaceuticals: Strong Market Position and Growth Potential Drive Buy Rating
Evercore ISI Analyst forecast on VRTX
Evercore ISI
Evercore ISI
$510$475
Buy
23.14%
Upside
Reiterated
09/11/25
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
BMO Capital Analyst forecast on VRTX
BMO Capital
BMO Capital
$530
Buy
37.40%
Upside
Reiterated
09/11/25
Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic PositioningRobust pipeline updates and our ongoing Journavx script tracking underpin our Outperform rating and a target price of $530.
Citi
$550
Buy
42.58%
Upside
Reiterated
09/10/25
Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
Raymond James Analyst forecast on VRTX
Raymond James
Raymond James
$401
Hold
3.96%
Upside
Initiated
09/02/25
Vertex Pharmaceuticals initiated with a Market Perform at Raymond JamesVertex Pharmaceuticals initiated with a Market Perform at Raymond James
Bernstein
Hold
Reiterated
08/22/25
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Goldman Sachs Analyst forecast on VRTX
Goldman Sachs
Goldman Sachs
$624
Buy
61.77%
Upside
Reiterated
08/11/25
Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on VRTX
Canaccord Genuity
Canaccord Genuity
$424$411
Hold
6.55%
Upside
Reiterated
08/06/25
Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord
Guggenheim
$558$546
Buy
41.55%
Upside
Reiterated
08/06/25
Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Wells Fargo Analyst forecast on VRTX
Wells Fargo
Wells Fargo
$460
Buy
19.25%
Upside
Upgraded
08/06/25
Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position
Truist Financial Analyst forecast on VRTX
Truist Financial
Truist Financial
$520$490
Buy
27.03%
Upside
Reiterated
08/05/25
Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on VRTX
H.C. Wainwright
H.C. Wainwright
$550$478
Buy
23.92%
Upside
Reiterated
08/05/25
Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month
xxx
Success Rate
24/32 ratings generated profit
75%
Average Return
+4.15%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +4.15% per trade.
3 Months
xxx
Success Rate
21/31 ratings generated profit
68%
Average Return
+6.15%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 67.74% of your transactions generating a profit, with an average return of +6.15% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
22/32 ratings generated profit
69%
Average Return
+19.89%
reiterated a buy rating 19 days ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +19.89% per trade.
2 Years
xxx
Success Rate
26/31 ratings generated profit
84%
Average Return
+24.42%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.87% of your transactions generating a profit, with an average return of +24.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
2
2
Buy
33
35
36
34
31
Hold
33
39
40
32
24
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
66
74
76
68
57
In the current month, VRTX has received 33 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 486.24.
Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $4.60 with a range of $4.33 to $5.01. The previous quarter’s EPS was $4.52. VRTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for VRTX is $4.60 with a range of $4.33 to $5.01. The previous quarter’s EPS was $4.52. VRTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.05B with a range of $2.94B to $3.14B. The previous quarter’s sales results were $2.99B. VRTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.
Next quarter’s sales forecast for VRTX is $3.05B with a range of $2.94B to $3.14B. The previous quarter’s sales results were $2.99B. VRTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year VRTX has Preformed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 486.24.
    What is VRTX’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals Inc. has 26.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRTX a Buy, Sell or Hold?
          Vertex Pharmaceuticals Inc. has a consensus rating of Moderate Buy which is based on 15 buy ratings, 10 hold ratings and 0 sell ratings.
            What is Vertex Pharmaceuticals Inc.’s price target?
            The average price target for Vertex Pharmaceuticals Inc. is 486.24. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $624.00 ,the lowest forecast is $401.00. The average price target represents 26.05% Increase from the current price of $385.74.
              What do analysts say about Vertex Pharmaceuticals Inc.?
              Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of VRTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis